ArticleJournal of clinical microbiology2019
Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.
Article in Journal of clinical microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Clinical performance of ASCL1/LHX8 DNA methylation on first-void urine to screen for cervical cancer.Communications medicine · 2026Article
- Article
- Article
- Cost-effectiveness analysis of reflex p16/Ki-67 dual-stained cytology in HPV partial genotyping screening in Singapore.Journal of gynecologic oncology · 2025Article
- Comparative clinical performance of Alinity m HR HPV, cobas 4800 HPV, and cobas 6800 HPV for cervical cancer screening.Microbiology spectrum · 2025Article
- Prevalence of HPV, cytological abnormalities, and impact of the HPV vaccine in Mexico: a Nationwide Study of 596,944 women.Lancet regional health. Americas · 2025Article
- Clinical validation of the Roche cobas HPV test on the Roche cobas 5800 system for the purpose of cervical screening.Microbiology spectrum · 2024Article
- Comparative Analysis of HPV Detection Efficiency: Evaluating Cobas 8800 Performance in Vaginal Self-Sampling versus Clinician-Collected Samples at a Regional Thai Hospital.Diagnostics (Basel, Switzerland) · 2024Article
- Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.Acta obstetricia et gynecologica Scandinavica · 2024Article
- Clinical Validation of the Vitro HPV Screening Assay for Its Use in Primary Cervical Cancer Screening.Cancers · 2024Article
- Cost-effectiveness of p16/Ki-67 Dual-Stained Cytology Reflex Following Co-testing with hrHPV Genotyping for Cervical Cancer Screening.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Clinical Performance of Cobas 6800 for the Detection of High-Risk Human Papillomavirus in Urine Samples.Vaccines · 2023Article
- Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program.American journal of clinical pathology · 2022Article
- Advances in HPV Screening Tests for Cervical Cancer-A Review.Journal of obstetrics and gynaecology of India · 2022Review
- Validation of the cobas 6800 human papillomavirus test in primary cervical screening.PloS one · 2021Article
- Article
- Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
- Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.Virology journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study demonstrates that the clinical sensitivity, specificity, and reproducibility of the novel cobas human papillomavirus (HPV) test on the cobas 6800 system for high-risk HPV types fulfills the criteria for use in population-based cervical screening. The criteria were formulated by an international consortium, using the cobas 4800 HPV test as a validated reference assay. The cobas HPV test detected over 98% of histologically confirmed cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions in women age 30 years or older, with a specificity of 98.9% compared with the reference cobas 4800 test. Both the intra- and interlaboratory agreement for the cobas HPV test were 98%. The clinical performance of the cobas HPV test is comparable to those of longitudinally validated HPV assays and fulfills the criteria for its use in primary cervical screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.